Back

Acute effect of empagliflozin on echocardiographic parameter in de novo heart failure: a secondary analysis of the EMPAG-HF trial

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Acute heart failure - pharmacotherapy 2 Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Jurgen Bogoviku

University hospital Jena, Jena (Germany)

6 More presentations in this session

Presentation thumbnail
The effect of statin persistence on prognosis in acute heart failure patients
Associate Professor H. Kim (Guri, KR)
Abstract Slides Video
Presentation thumbnail
Acute diuretic effect of empagliflozin in de novo heart failure: a secondary analysis of the EMPAG-HF trial
Doctor J. Bogoviku (Jena, DE)
Abstract Slides Video
Presentation thumbnail
Renal function in patients with acute decompensated de novo heart failure treated with the SGLT2 inhibitor empagliflozin: a secondary analysis of the EMPAG-HF trial
Doctor J. Bogoviku (Jena, DE)
Abstract Slides Video
Presentation thumbnail
Impact of af on sacubitril/valsartan dosing, persistance of treatment and associated outcomes in heart failure patients with reduced ejection fraction
Doctor N. Bonini (Modena, IT)
Abstract Slides Video
Presentation thumbnail
Acute diuretic response of empagliflozin according to LVEF:A secondary analysis of the EMPAG-HF trial
Doctor J. Bogoviku (Jena, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Acute heart failure - pharmacotherapy 2

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Acute diuretic effect of empagliflozin in de novo heart failure: a secondary analysis of the EMPAG-HF trial
thumbnail
Congress Presentation
Renal function in patients with acute decompensated de novo heart failure treated with the SGLT2 inhibitor empagliflozin: a secondary analysis of the EMPAG-HF trial
thumbnail
Congress Presentation
Acute diuretic response of empagliflozin according to LVEF:A secondary analysis of the EMPAG-HF trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources